CN100430071C - Medicine for lowering blood sugar and treating women menopausal syndrome and preparation method thereof - Google Patents
Medicine for lowering blood sugar and treating women menopausal syndrome and preparation method thereof Download PDFInfo
- Publication number
- CN100430071C CN100430071C CNB2004101039857A CN200410103985A CN100430071C CN 100430071 C CN100430071 C CN 100430071C CN B2004101039857 A CNB2004101039857 A CN B2004101039857A CN 200410103985 A CN200410103985 A CN 200410103985A CN 100430071 C CN100430071 C CN 100430071C
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- given
- wine
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a new medicine for treating diabetes and climacteric syndrome of women, which is mainly prepared by the following method: pigeon pea leaf is extracted in alcohol, and after extractin liquid is filtered, the extraction liquid is decompressed and concentrated to obtain wine extractum; the wine extractum is dissolved in water and is filtered, filter liquor passes through macroporous resin and is desorbed in alcohol, methanol or propanone, and an obtained organic solution is decompressed and concentrated until the organic solution is dry. Experiments indicate that the medicine of the present invention is suitable for treating diabetes and climacteric syndrome of women.
Description
Technical field
The present invention relates to medicine of a kind of blood sugar lowering and treatment climacteric syndrome and preparation method thereof, belong to life science.
Background technology
In the prior art, cajanin, Longistylin A, Longistylin C, pinostrobin, vitexin, isovitexin, apigenin, luteolin etc. had once been reported from the Folium Cajani isolation identification.Former three belongs to the stilbene constituents, and all the other are flavonoid.Because structural difference, this two class (even similar and different structure) composition, their biological activity is different.Report more have antitumor, cardiac vascular activity, antioxidation and antibiotic etc.But do not see the content that the present invention relates to is arranged.
Summary of the invention
Technical problem to be solved by this invention provides a kind of new medicine that can effectively treat diabetes and climacteric syndrome.
Technical problem to be solved by this invention realizes by following technological approaches:
A kind of medicine for the treatment of diabetes and climacteric syndrome is prepared from by following method:
1), Folium Cajani pulverized after, use ethanol extraction, concentrating under reduced pressure gets steeping in wine cream behind the extracting liquid filtering.
2), above-mentioned steeping in wine cream is soluble in water, filter, filtrate is by macroporous adsorbent resin and with ethanol, methanol or acetone desorbing, the organic solution of gained is evaporated to dried, promptly.
In the drug prepared of the present invention, mainly contain Semen Cajani stilbene and Semen Cajani flavone component, can effectively treat diabetes and climacteric syndrome, also can be used for due to illness spay or chemicotherapy and cause artificial menopause women's treatment.
Further describe beneficial effect of the present invention by the following examples, it should be understood that these embodiment only are used for the purpose of illustration, never limit the scope of the invention.
The specific embodiment
The preparation of [embodiment] medicine of the present invention
The Folium Cajani 4kg that pulverizes adds 80% ethanol and crosses face, is heated to and boils, be incubated one hour, filter repetitive operation three times, the filtrate decompression that merges is concentrated into does not have the alcohol flavor, 1kg steeping in wine cream, the steeping in wine cream of gained is added 70 ℃ of hot water changes molten, filters (kieselguhr helps filter), the filtrate that obtains is passed through macroporous adsorptive resins, alcohol desorption, the alcoholic solution that obtains is evaporated to dried 164g Folium Cajani extract (I).
The hypoglycemic activity test of [test example 1] medicine of the present invention
One, test material and method
1, experimental animal: 60 of male mouse of kunming, body weight 20.56 ± 0.86g is available from animal institute of the Chinese Academy of Medical Sciences.
2, given the test agent: the Folium Cajani extract (I) that the embodiment of the invention 1 is prepared.
3, positive control drug: phenformin hydrochloride tablet (JIANGZHILING PIAN) (Shandong Boshan Pharmaceutical Co., Ltd., lot number 0206272).
4, laboratory animal grouping: being divided into is five groups, i.e. the high, medium and low dosage group of blank group, positive drug control group and given the test agent, every group of 12 animals.
5, modeling method: mice absolute fasting (changing bedding and padding) be can't help water after 18 hours, intraperitoneal administration chain urase element (Streptozotocin) 200mg/kg.(Sigma company product, lot number 971201)
6, testing index: body weight, fasting glucose and postprandial plasma glucose level (carbohydrate tolerance).
7, administration: gastric infusion, every day 1 time, a continuous week.The high, medium and low dosage group of given the test agent is given Folium Cajani extract 1200,600,300mg/kg respectively.The blank model group is given normal saline.
8, blood-sugar level measuring: water administration after 8 hours is can't help in mice absolute fasting (changing bedding and padding), and administration was got blood after 1 hour, measures the serum glucose value, sees Table 1.
9, carbohydrate tolerance test: administration is after 1 hour, and 2g/kg starch (10%) load is measured and given the sugar back 1,2 hour blood glucose value, sees Table 2.
Two, result of the test
The result: given the test agent high dose group and normal saline model control group compare, and the fasting blood sugar of administration group and postprandial plasma glucose level all have tangible reduction, have statistical significance, P＜0.05, and show dose-effect relationship.Given the test agent high dose group and positive control drug group (200mg/kg) compare, and not only hypoglycemic effect is better than insoral, and aspect increasing the weight of animals and reducing the animal dead rate, demonstrate its superiority (table 1 and table 2).
Table 1. Folium Cajani extract is to the influence of diabetic mice fasting glucose
* P＜0.05 (with the comparison of blank group)
[test example 2] medicine of the present invention is tested HOS human osteoblast proliferation function.
One, test material and method
Cell strain: HOS TE85 human osteoblast strain (from Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences).
Drug treating time: 48 hours.
Observation index: 1. cell proliferation (MTT); 2.
3The H-proline participates in; 3. alkaline phosphatase activities
Given the test agent: embodiment of the invention drug prepared and cajanin monomer component.
Positive control medicine: estradiol (E
2) (the sharp bioid in sky, Beijing factory product).
Result of the test: be respectively 10 at final concentration
-7With 10
-8During g/ml, monomer cajanin and given the test agent can dose-dependent promotion osteoblastic proliferation, the collagen formation of energy irritation cell simultaneously.Show that they have the effect of stimulating osteoblast bone formation, but they are to not influence (seeing Table 3) of alkaline phosphatase activity.
Table 3. Folium Cajani extract is to the function of HOS TE85 cell bone formation
* P＜0.05; * P＜0.01 (comparing) with the blank group
[test example 3] medicine of the present invention is to the influence of removal ovary rat model
One, test material and method:
1, laboratory animal: 60 female WISTAR rats that grow up, body weight 232.7g ± 11.0g is available from animal institute of the Chinese Academy of Medical Sciences.
2, animal model: adopting and removing bilateral ovaries (castration) rat is model.Concrete operations are as follows: cut rat abdomen, separate and the excision bilateral ovaries, sew up the abdominal cavity then.The Sham-operated control group rat, abdominal incision separates bilateral ovaries, is equivalent to the fat of ovary size near the spay, sews up then and closes the abdominal cavity.
3, given the test agent: embodiment of the invention drug prepared, to join and be high, medium and low dosage group, its concentration is respectively: 200mg/kg; 100mg/kg; 50mg/kg.
4, positive control drug: estradiol (E
2) (the sharp bioid in sky, Beijing factory product), administration concentration is 0.5mg/kg.
5, experimental animal grouping (n=number of animals):
1. Sham-operated control group (n=8).
2. blank model group (n=11).
3. positive drug (E
2) matched group (n=11): the positive drug group is given E
20.5mg/kg the rat castration is after two weeks, every day gastric infusion once, continuous eight weeks.
4. given the test agent administration group (n=10): the high, medium and low dosage group of given the test agent administration concentration respectively is: 200mg/kg, 100mg/kg, 50mg/kg.The rat castration is after two weeks, every day gastric infusion once, continuous eight weeks.
6, testing index: body weight, uterus weight and ovary weight, hormone serum level (putting the method for exempting from measures), the cut sections for microscopic examination of osteopathia reason.
Result of the test:
1. to the influence of castrated rats body weight and uterus weight: model group is compared with sham operated rats, and rat body weight obviously increases.After the administration, positive drug group and given the test agent height, middle dosage group rat body weight descend to some extent than model group; The model group uterus weight only is 20% of a sham operated rats; And the estradiol group is compared with model group, and rat uterus weight has increased by 108.3%, but still is lower than sham operated rats.Different with the estradiol group, the uterus weight of each dosage group of given the test agent does not obviously increase, and shows that it does not have stimulation to the uterus.
2. to the influence of castrated rats hormone serum level: after the excision of model group rat ovary, serum estradiol content obviously reduces, and FSH and LH obviously increase simultaneously; Give E
2After positive controls, with model group relatively, serum E
2Content increases by 57.7%, and FSH and LH reduce by 11.5% and 20.7% respectively.Given the test agent high dose group and model group compare, serum E
2Content does not obviously increase, and FSH and LH then reduce by 11.5% and 15.2% respectively.Result of the test shows that medicine of the present invention can improve because the serum estrogen level reduces caused FSH and LH raises.
3. the influence that castrated rats osteopathia reason is changed: positive drug control group is being given E
2After, the bone loss of 82% rat femur has obtained recovery.The high dose group rat of given the test agent treatment then has the bone loss of 60% femur to improve, and middle dosage is 30% to improve.Show that medicine of the present invention has the bone loss of inhibition, promotes the bone formation effect.
Claims (1)
1, the Folium Cajani extract causes that in preparation treatment diabetes, climacteric syndrome, oophorectomize artificial menopause or chemicotherapy cause the purposes in the medicine of artificial menopause; Wherein, described Folium Cajani extract is prepared from according to following step:
(1), with the Folium Cajani ethanol extraction, concentrating under reduced pressure gets steeping in wine cream behind the extracting liquid filtering;
(2), above-mentioned steeping in wine cream is soluble in water, filter, filtrate is by macroporous adsorbent resin and with ethanol, methanol or acetone desorbing, the organic solution of gained is evaporated to dried, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004101039857A CN100430071C (en) | 2004-12-31 | 2004-12-31 | Medicine for lowering blood sugar and treating women menopausal syndrome and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004101039857A CN100430071C (en) | 2004-12-31 | 2004-12-31 | Medicine for lowering blood sugar and treating women menopausal syndrome and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1799571A CN1799571A (en) | 2006-07-12 |
| CN100430071C true CN100430071C (en) | 2008-11-05 |
Family
ID=36809931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004101039857A Expired - Fee Related CN100430071C (en) | 2004-12-31 | 2004-12-31 | Medicine for lowering blood sugar and treating women menopausal syndrome and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100430071C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000078324A1 (en) * | 1999-06-18 | 2000-12-28 | Hao Yuan | The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof |
-
2004
- 2004-12-31 CN CNB2004101039857A patent/CN100430071C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000078324A1 (en) * | 1999-06-18 | 2000-12-28 | Hao Yuan | The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| 生脉成骨片中木豆叶提取工艺研究. 刘中秋，周华，林励，廖惠芳，周莉玲.中成药，第3期. 1998 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1799571A (en) | 2006-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102458434B (en) | Composition for increasing the bioavailability of saponin | |
| CN111840363B (en) | Natto-assisted hypoglycemic health-care composition and preparation method and application thereof | |
| CN107080250A (en) | A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof | |
| CN104173451A (en) | Application of natural pharmaceutical composition in blood glucose-reducing drugs and health food | |
| CN102319256B (en) | Application of porphyra polysaccharide in preparing treatment medicament or prevention health-care product of kidney diseases | |
| CN1861104B (en) | Inula flower extractive used to breat diabets mellitus and hyperlipidemia | |
| CN102283913A (en) | Radix aconiti carmichaeli extract and application thereof | |
| KR101719709B1 (en) | Composition for preventing or treating metabolic disorders comprising extracts of Lonicera japonica Thunb. and Rehmannia glutinosa Liboch | |
| CN104337884A (en) | Medicine composition for preventing and/or treating diabetes and complication of diabetes | |
| CN101948473B (en) | New NEO-clerodane diterpenoid compound and application thereof | |
| KR0160108B1 (en) | Anticancer agent of raw ingredient extracted from the tree named gleditschia officinalis | |
| CN102935104A (en) | Maackia amurensis total flavone extract, as well as preparation method and application thereof | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN100430071C (en) | Medicine for lowering blood sugar and treating women menopausal syndrome and preparation method thereof | |
| CN101077873B (en) | Novel NEO-clerodane type diterpene compound and application thereof | |
| KR20170024689A (en) | Food composition for bowel movement promotion and diet using herbal material | |
| CN104815140A (en) | Composition for preventing or/and treating diabetes and preparation method of composition | |
| CN101450162A (en) | Traditional Chinese medicine composition with blood-sugar reduction function and preparation method thereof | |
| KR100750873B1 (en) | A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease | |
| CN108498563A (en) | A kind of chitosan composite and preparation method thereof | |
| CN104940428B (en) | Hypoglycemic composition containing wolfberry fruits and application thereof | |
| CN108096270A (en) | A kind of pharmaceutical composition for treating diabetic nephropathy | |
| EP2556837A1 (en) | Traditional chinese medicine composition for treating hyperglycemia and preparation method thereof | |
| CN1919229B (en) | Bauhinia hupehara C. and its extract for the treatment of diabetes and obesity | |
| CN108743654B (en) | Traditional Chinese medicine composition for treating ischemic heart disease and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081105 Termination date: 20171231 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |